VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study-Reference-Cited by-同舟云学术

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

Published:2022-04 Issue:4 Volume:33 Page:451-453
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Paz-Ares L.,O'Brien M.E.R.,Mauer M.,Dafni U.,Oselin K.,Havel L.,Esteban Gonzalez E.,Isla D.,Martinez-Marti A.,Faehling M.,Tsuboi M.,Lee J-S.,Nakagawa K.,Yang J.,Keller S.M.,Jha N.,Marreaud S.I.,Stahel R.A.,Peters S.,Besse B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature;Cancer Treatment Reviews;2024-09

2. Pathologische Diagnostik und Biomarker für die perioperative Systemtherapie;Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie;2024-08

3. What Does N2 Lymph Node Involvement Mean for Patients with Non-Small Cell Lung Cancer (NSCLC)?—A Review of Implications for Diagnosis and Treatment;Cancers;2024-07-26

4. The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma;iScience;2024-07

5. Revolutionizing Localized Lung Cancer Treatment: Neoadjuvant Chemotherapy plus Immunotherapy for All?;Journal of Clinical Medicine;2024-05-05